Precision BioSciences (NASDAQ:DTIL) Rating Reiterated by HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $60.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 459.70% from the stock’s current price.

Precision BioSciences Price Performance

Shares of DTIL stock opened at $10.72 on Wednesday. Precision BioSciences has a fifty-two week low of $8.25 and a fifty-two week high of $28.44. The stock’s 50-day moving average is $13.01 and its two-hundred day moving average is $11.75. The firm has a market cap of $74.18 million, a P/E ratio of -0.67 and a beta of 1.53.

Insider Transactions at Precision BioSciences

In other news, CEO Michael Amoroso sold 4,579 shares of the company’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $10.80, for a total transaction of $49,453.20. Following the completion of the sale, the chief executive officer now owns 11,881 shares in the company, valued at approximately $128,314.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 6,005 shares of company stock worth $64,854. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of Precision BioSciences

Several hedge funds have recently added to or reduced their stakes in the business. Balyasny Asset Management LLC lifted its position in shares of Precision BioSciences by 70.1% in the 3rd quarter. Balyasny Asset Management LLC now owns 19,333 shares of the company’s stock worth $25,000 after acquiring an additional 7,967 shares during the period. Swiss National Bank lifted its position in shares of Precision BioSciences by 9.5% in the 1st quarter. Swiss National Bank now owns 114,900 shares of the company’s stock worth $354,000 after acquiring an additional 10,000 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Precision BioSciences in the 1st quarter worth approximately $34,000. Quantbot Technologies LP bought a new stake in shares of Precision BioSciences in the 1st quarter worth approximately $35,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Precision BioSciences by 3.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 362,455 shares of the company’s stock worth $1,117,000 after acquiring an additional 12,847 shares during the period. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.